systematic-literature-review-and-network-meta-analysis-of-therapies-for-psoriatic-arthritis-on-patient-reported-outcomes 2023-11-09T19:25:10.411Z 3665f6cd-25c6-4c1b-9a81-3f61a93a68e4 ab8b4819-55dc-4ab6-99e1-0178e38cd210 mas_evidence_types:Systematic%20reviews Systematic reviews and meta-analyses Review (26 RCTs) found that while intravenous TNFs may provide some improvements in patient-reported outcomes relative to several other targeted synthetic DMARDs and biologic DMARDs, differences between classes of therapies across outcomes were small. <p>Studies evaluated inhibitors of the following treatment classes: cytotoxic T-lymphocyte-associated antigen 4 (abatacept), IL-12/23 (ustekinumab), IL-17A (ixekizumab, secukinumab), IL-23 (guselkumab), Janus kinase (tofacitinib), subcutaneous TNF (adalimumab, certolizumab, etanercept, golimumab), intravenous TNF (golimumab, infliximab) and phosphodiesterase-4 (apremilast). The IL-17 receptor A inhibitor brodalumab and JAK inhibitor upadacitinib were not approved at the time of the search (October 2018 to January 2020).</p> https://www.medicinesresources.nhs.uk/systematic-literature-review-and-network-meta-analysis-of-therapies-for-psoriatic-arthritis-on-patient-reported-outcomes.html https://bmjopen.bmj.com/content/13/11/e062306 2023-11-08T00:00:00Z 2023-11-09T16:26:59.861Z